Search - tctmd.com

Displaying 121 - 140 of 375

Sort: Relevancy | Date

Presentation TCT 2017

NOBLE: Core Findings Revisited and New Data

Presenter: Antonio Colombo, David E. Kandzari, Evald H. Christiansen

October 31, 2017

EXCEL: Core Findings Revisited and New Data

Presentation TCT 2017

EXCEL Trial 3-Year Results Updated and New Data

Presenter: Antonio Colombo, David E. Kandzari, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

TCT 84: Procedural Strategy and Clinical Outcomes in Patients Undergoing PCI for Left Main Trifurcation Disease: The EXCEL Trial

Presenter: David Hildick-Smith, Nicholas J. Lembo, David E. Kandzari

October 31, 2017

Presentation TCT 2017

TCT 83: Provisional vs Planned Two-Stent Technique in Patients With Distal Bifurcation Left Main Disease Undergoing PCI: The EXCEL Trial

Presenter: David Hildick-Smith, Nicholas J. Lembo, David E. Kandzari

October 31, 2017

Presentation TCT 2017

BioNIR: Specifications and BIONICS/NIREUS Results in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari

October 30, 2017

Presentation TCT 2017

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Sigmund Silber

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Daily News

Despite the Strengths of Next-Gen DES, BMS Deserve a Place at the Cath Table, Review Asserts

Caitlin E. Cox

July 28, 2017

Podcast TCTMD Talking Points

Episode 24: BIONICS - Ridaforolimus-Eluting vs Zotarolimus-Eluting Stents in a More-Comers Population

July 05, 2017

News Daily News

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

Yael L. Maxwell

June 30, 2017

Presentation Fellows 2017

High-Risk PCI and Cardiogenic Shock: The Role of Hemodynamic Support

Presenter: Ajay J. Kirtane, David E. Kandzari

April 08, 2017

Presentation Fellows 2017

Left Main Disease: PCI vs CABG

Presenter: Emmanouil S. Brilakis, David E. Kandzari

April 08, 2017

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

Presentation CTO 2017

Three Year Outcomes From the EXPERT CTO Trial

Presenter: Evald H. Christiansen, Robert W. Yeh, David E. Kandzari

February 24, 2017

Presentation CTO 2017

Data From the PERSPECTIVE Registry

Presenter: Evald H. Christiansen, Robert W. Yeh, David E. Kandzari

February 24, 2017

Presentation CHIP Florida 2017

Evolution of Left Main Percutaneous Revascularization Advancement to a Standard of Care

Presenter: David E. Kandzari

January 20, 2017

Advertisement

NOBLE: Core Findings Revisited and New Data

EXCEL Trial 3-Year Results Updated and New Data

TCT 84: Procedural Strategy and Clinical Outcomes in Patients Undergoing PCI for Left Main Trifurcation Disease: The EXCEL Trial

TCT 83: Provisional vs Planned Two-Stent Technique in Patients With Distal Bifurcation Left Main Disease Undergoing PCI: The EXCEL Trial

BioNIR: Specifications and BIONICS/NIREUS Results in Perspective

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Despite the Strengths of Next-Gen DES, BMS Deserve a Place at the Cath Table, Review Asserts

Episode 24: BIONICS - Ridaforolimus-Eluting vs Zotarolimus-Eluting Stents in a More-Comers Population

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

High-Risk PCI and Cardiogenic Shock: The Role of Hemodynamic Support

Left Main Disease: PCI vs CABG

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Three Year Outcomes From the EXPERT CTO Trial

Data From the PERSPECTIVE Registry

Evolution of Left Main Percutaneous Revascularization Advancement to a Standard of Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content